Clinical Trial

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-12
notable Trial sites expanded: 0 -> 5 locations 2026-08-12
Trial Details
NCT Number NCT07533708
Lead Sponsor Shanghai Henlius Biotech
Conditions mCRPC or Advanced/Metastatic Solid Tumors
Enrollment 48 participants
Start Date 2026-07-30
Primary Completion 2027-06-29 (estimated)
Study Completion 2028-05-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-11